Drug Type Antibody oligonucleotide conjugates |
Synonyms DMD exon 45(Avidity), AOC 1045, AOC1045 |
Target |
Action modulators |
Mechanism DMD exon 45 modulators(Dystrophin exon 45 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Muscular Dystrophy, Duchenne | Preclinical | United States | 01 Nov 2024 |






